Otologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing function resulting from chronic and age-related hearing loss. Currently, no pharmacological treatment for hearing loss is available. The status of OPI’s programs is as follows: •NHPN-1010 (HPN-07 plus N-acetylcysteine, NAC) completed two Phase 1 safety/pharmacokinetic studies in healthy volunteers, and is anticipated to enter a Phase 2 trial in collaboration with Oblato. •Preclinical siRNA program for regeneration of auditory sensory epithelia (hair cells) in the cochlea lost as a result of age-related hearing loss or chronic NIHL, has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss. Press Releases: https://www.prnewswire.com/news-releases/oblato-biotech-company-acquires-hearing-loss-drug-discovered-by-hough-ear-institute-scientists-301003204.html